At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
COL-101 (doxycycline, USP) capsules +1 moredrug
Likely dose
COL-101 (doxycycline, USP) capsules 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea
In Brief
A Phase 2 clinical trial evaluating COL-101 (doxycycline, USP) capsules and placebo for Blepharitis and 2 related conditions. Completed, enrolled 70 participants across 8 sites.
Detailed Summary
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharitis, Meibomianitis, Dry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionMay 2009
Study CompletionJul 2009
TodayJul 2026
First PostedNov 20, 2007
Enrollment StartNov 1, 2007
Primary CompletionMay 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.6 years ago
Interventions
COL-101 (doxycycline, USP) capsulesdrug
40mg, once per day for 84 days
placebodrug
sugar capsule